The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Metal-based anticancer chemotherapeutic agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Self-citationAreneruthenium complexes as anticancer agents
Süß‐Fink, G. (2009) · Dalton Transactions · doi:10.1039/b916860p · Cited by 652
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Research works printed but not linked: 21
- Kozubik, 2005, High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro, Biochem Pharmacol, 69, 373, 10.1016/j.bcp.2004.09.005 · doi:10.1016/j.bcp.2004.09.005
- Medrano, 2013, Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs, Chem Commun (Camb), 49, 4806, 10.1039/c3cc38416k · doi:10.1039/c3cc38416k
- Varbanov, 2012, Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs, Dalton Trans, 41, 14404, 10.1039/C2DT31366A · doi:10.1039/c2dt31366a
- Ravera, 2012, Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin, Dalton Trans, 41, 3313, 10.1039/c2dt11874b · doi:10.1039/c2dt11874b
- Pichler, 2013, Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes, Inorg Chem, 52, 8151, 10.1021/ic400816g · doi:10.1021/ic400816g
- Farrer, 2010, A potent trans-diimine platinum anticancer complex photoactivated by visible light, Angew Chem Int Ed, 49, 8905, 10.1002/anie.201003399 · doi:10.1002/anie.201003399
- Wedlock, 2013, NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound, Chem Commun (Camb), 49, 6944, 10.1039/c3cc42098a · doi:10.1039/c3cc42098a
- Manzotti, 2000, BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin, Clin Cancer Res, 6, 2626
- Zhao, 2006, A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity, Dalton Trans, 2617, 10.1039/b601739h · doi:10.1039/b601739h
- Wang, 2011, Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin, Inorg Chem, 50, 12661, 10.1021/ic201712e · doi:10.1021/ic201712e
- Zerzankova, 2010, Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers, Biochem Pharmacol, 80, 344, 10.1016/j.bcp.2010.04.013 · doi:10.1016/j.bcp.2010.04.013
- Komeda, 2011, A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer, ChemMedChem, 6, 987, 10.1002/cmdc.201100141 · doi:10.1002/cmdc.201100141
- Komeda, 2013, Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles, Metallomics, 5, 461, 10.1039/c3mt00040k · doi:10.1039/c3mt00040k
- Brown, 2012, Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity, Dalton Trans, 41, 11330, 10.1039/c2dt31313h · doi:10.1039/c2dt31313h
- Lakomska, 2013, Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands, Dalton Trans, 42, 6219, 10.1039/c2dt32216a · doi:10.1039/c2dt32216a
- Li, 2012, Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers, Dalton Trans, 41, 1138, 10.1039/C1DT11950H · doi:10.1039/c1dt11950h
- Kilpin, 2013, Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands, Dalton Trans, 42, 2008, 10.1039/C2DT32333H · doi:10.1039/c2dt32333h
- Khan, 2013, Arene ruthenium dichloro complexes containing isonicotinic ester ligands: synthesis, molecular structure and cytotoxicity, J Organomet Chem, 730, 49, 10.1016/j.jorganchem.2012.10.016 · doi:10.1016/j.jorganchem.2012.10.016
- Serratrice, 2012, Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1, Dalton Trans, 41, 3287, 10.1039/c2dt11913g · DOI
- Ronconi, 2009, The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes, Dalton Trans, 10670, 10.1039/b913597a · doi:10.1039/b913597a
- Meker, 2012, High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species, Angew Chem Int Ed Engl, 51, 10515, 10.1002/anie.201205973 · doi:10.1002/anie.201205973
Cited by
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Self-citationHypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Schiff bases in medicinal chemistry: a patent review (2010-2015)
Hameed, A., al-Rashida, M., Uroos, M., Abid Ali, S., & Khan, K. M. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1252752 · Cited by 401
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
The elements of life and medicines
Chellan, P., & Sadler, P. J. (2015) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2014.0182 · Cited by 274
A small molecule HIF-1α stabilizer that accelerates diabetic wound healing
Li, G., Ko, C.-N., Li, D., Yang, C., Wang, W., Yang, G.-J., Di Primo, C., Wong, V. K. W., Xiang, Y., Lin, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23448-7 · Cited by 261
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
New trends in platinum and palladium complexes as antineoplastic agents
Fanelli, M., Formica, M., Fusi, V., Giorgi, L., Micheloni, M., & Paoli, P. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.11.004 · Cited by 258
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21].”
Metadata
- Authors
- Muhammad, N., & Guo, Z.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 19
- Pages
- 144-153
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2090858808
- Cited by
- 515
- References
- 32
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Basic Research Program of China (2011CB935800)
- National Natural Science Foundation of China (21271100, 91213305, 10979019, 21131003, 21021062)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.